Abstract:Bone morphogenetic proteins (BMPs) are secreted cytokines that were initially discovered on the basis of their ability to induce bone. Several decades of research have now established that these proteins function in a large variety of physiopathological processes. There are about 15 BMP family members, which signal via three transmembrane type II receptors and four transmembrane type I receptors. Mechanistically, BMP binding leads to phosphorylation of the type I receptor by the type II receptor. This activated heteromeric complex triggers intracellular signaling that is initiated by phosphorylation of receptor‐regulated SMAD1, 5, and 8 (also termed R‐SMADs). Activated R‐SMADs form heteromeric complexes with SMAD4, which engage in specific transcriptional responses. There is convergence along the signaling pathway and, besides the canonical SMAD pathway, BMP‐receptor activation can also induce non‐SMAD signaling. Each step in the pathway is fine‐tuned by positive and negative regulation and crosstalk with other signaling pathways. For example, ligand bioavailability for the receptor can be regulated by ligand‐binding proteins that sequester the ligand from interacting with receptors. Accessory co‐receptors, also known as BMP type III receptors, lack intrinsic enzymatic activity but enhance BMP signaling by presenting ligands to receptors. In this review, we discuss the role of BMP receptor signaling and how corruption of this pathway contributes to cardiovascular and musculoskeletal diseases and cancer. We describe pharmacological tools to interrogate the function of BMP receptor signaling in specific biological processes and focus on how these agents can be used as drugs to inhibit or activate the function of the receptor, thereby normalizing dysregulated BMP signaling. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Targeting BMP signalling in cardiovascular disease and anaemia

BMP Signaling in the Development and Regeneration of Cranium Bones and Maintenance of Calvarial Stem Cells.

BMP Signaling in Vascular Diseases

BMP signaling in vascular diseases.

Bone Morphogenetic Proteins in Vascular Homeostasis and Disease

Bone Morphogenetic Protein Receptors: Structure, Function and Targeting by Selective Small Molecule Kinase Inhibitors

Bone Morphogenetic Protein Receptor Signal Transduction in Human Disease

Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection

Insights into bone morphogenetic proteins in cardiovascular diseases.

BMP Type II Receptor As a Therapeutic Target in Pulmonary Arterial Hypertension.

Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension

Large-scale phosphoproteomics reveals activation of the MAPK/GADD45β/P38 axis and cell cycle inhibition in response to BMP9 and BMP10 stimulation in endothelial cells

Novel Advances in Modifying BMPR2 Signaling in PAH

Bone morphogenetic protein signaling in bone homeostasis

Bone Morphogenetic Protein Signaling in Bone Homeostasis.

The Role of Bone Morphogenetic Protein 7 (BMP-7) in Inflammation in Heart Diseases

TGF-β and BMPR2 Signaling in PAH: Two Black Sheep in One Family

Adverse effects of BMPR2 suppression in macrophages in animal models of pulmonary hypertension

Bone morphogenetic protein 10, a rising star in the field of diabetes and cardiovascular disease

Effects of Modulating BMP9, BMPR2, and AQP1 on BMP Signaling in Human Pulmonary Microvascular Endothelial Cells